Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC

Eastern Hepatobiliary Surgery Hospital300 enrolled

Overview

To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients after operation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

300

Conditions

Hepatocellular Carcinoma Rapamycin

Interventions

RapamycinDRUG

2mg,po,bid

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Via clinical diagnosis and confirm it is primary liver cancer 2. Pathological evidence of HCC 3. Estimate tumor can gain treatment of curing operation 4. No evidence for extrahepatic metestasis 5. liver function ：Child-Pugh A/B 6. BCLC stage：0/1；TNM stage：Ⅰ Exclusion Criteria: 1. reject to attend； 2. impossible to come to our hospital for physical examination regularly. 3. cancer epitome、seed focus、lymph node or distant metastasis 4. Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.

Locations (1)

Eastern hepatobilliary surgery hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Overall Survival

Time frame: 3 years

Secondary Outcomes

Time to recurrence

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.